Biological characteristics and genetic abnormalities in very, young patients with lung cancer (【less than or equal】30 years of age)

极年轻肺癌患者（【小于等于】30岁）的生物学特征及基因异常

• 批准号: 12670424
• 负责人: KIURA Katsuyuki
• 金额: $ 1.92万
• 依托单位: OKAYAMA UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12670424/
• 关键词: Lung Cancer; Early onset; p53; Li-Fraumeni syndrome; CD34; EBC-2; SBC-3; p16; Li-Faumeni症候群

Retrospectively, 20 patients with lung cancer aged【less than or equal】30 years from three Institutions were compared with 1848 patients of aged >30 years admitted to National Shikoku Cancer Center between 1981 and 2001. Median survival time (MST) and other factors were assessed using the Cox regression model and the chi-square test, respectively. In a multivariate analysis of the all population of lung cancer (n=1851), male gender, clinical symptoms, weight loss, a high LDH level, performance status (PS) of 【greater than or equal】2, and advanced-stage were independent negative prognostic factors. We found four patients with mucoepidermoid carcinoma among 20 patients of aged 【less than or equal】30 years. Mucoepidermoid carcinoma was excluded because of a high incidence (p<0.001) in the very young population, relatively early stage and longer survival time. The incidence of nonsmokers (p<0.001) and poorly differentiated non-small cell lung cancer (p=0.018) was also high in the very young … More group. In a multivariate analysis (n=16), clinical symptoms, LDH levels, and PS were also independent prognostic factors. There was no difference in survival between the young population and the general population. According to LDH levels and clinical symptoms, we classified the very young patients into three groups ; Group I : LDH (normal) and no clinical symptoms, Group II : LDH (normal) and clinical symptoms, and Group III : LDH (high) and clinical symptoms. The MST for group I, II and III were 50.0, 13.4, and 2.5 months, respectively (p=0.002). Excluding mucoepidermoid carcinoma, patients with a high LDH level and clinical symptoms showed poor prognosis in the very young population. Survival in the very young population was similar to that in the general population.We analyzed human lung cancer cell lines, SBC-3 and EBC-2 established in our laboratory. SBC-3 cells were derived from 24-year-old man with small-cell lung cancer, and EBC-2 cells from 20-year-old man with squamous cell carcinoma of the lung. SBC-3 cells showed heterozygous mutation codon 175 CGG to CAC (Arg to his) in Exon 5 of p58. EBC-2 showed desmosome and tonofilament be electron microscopy, and expressed drug resistant genes, MRP1, 3, 4, 5, and LRP, but LRP-2 and P-glycoprotein were not detected. Both SBC-3 and EBC-2 cells expressed CD34 by flow cytometry. Less

回顾性地，将三个机构的20例肺癌患者与1981年至2001年之间被接受为国家Shikoku Cancer Center接受的1848名年龄> 30岁的患者进行了比较。分别使用COX回归模型和CHI-SQUARE测试评估了中位生存时间（MST）。在对所有肺癌种群（n = 1851）的多元分析中，男性性别，临床症状，体重减轻，高LDH水平，高度表现状态（PS）为[大于或相等] 2，而晚期则是独立的负预后因素。我们发现了20例老年患者[小于或等于] 30年的患者中有四名粘膜外皮样癌患者。由于非常年轻的人群，相对较早的阶段和较长的生存时间，粘膜皮肤类癌被排除在外（P <0.001）。在非常年轻的组中，非吸烟者（p <0.001）和分化差的非小细胞肺癌（P = 0.018）的发生率也很高。在多元分析（n = 16）中，临床症状，LDH水平和PS也是独立的预后因素。年轻人口与普通人群之间的生存没有差异。根据LDH水平和临床症状，我们将非常年轻的患者分为三组。 I组：LDH（正常）和没有临床症状，II组：LDH（正常）和临床症状，以及III组：LDH（高）和临床症状。 I，II和III组的MST分别为50.0、13.4和2.5个月（p = 0.002）。除粘膜外皮类癌外，LDH水平高且临床症状的患者在很小的人群中的预后不良。我们非常年轻的人群的生存与普通人群相似。我们分析了在我们的实验室中建立的人类肺癌细胞系，SBC-3和EBC-2。 SBC-3细胞来自患有小细胞肺癌的24岁男性，以及来自肺部方形细胞癌的20岁男子的EBC-2细胞。 SBC-3细胞显示杂合突变密码子175 CGG至CAC（在P58的外显子5中）。 EBC-2表现出脱骨体和核丝是电子显微镜，并且表达耐药基因MRP1、3、4、5和LRP，但未检测到LRP-2和P-糖蛋白。 SBC-3和EBC-2细胞均通过流式细胞仪表达CD34。较少的

项目成果

Kawai H, Kiura K.Tabata M., et al.: "Characterization of Non-Small-Cell lung Cancer Cell Lines Established before and after Chemotherapy"Lung Cancer. 35・3. 305-314 (2003)

Kawai H、Kiura K.Tabata M.等人：“化疗前后建立的非小细胞肺癌细胞系的表征”35・3（2003）。

Y Segawa,H Ueoka, K Kiura, et al.: "A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer"British Journal of Cancer. 82・1. 104-111 (2000)

Y Sekawa、H Ueoka、K Kiura 等人：“顺铂和 5-氟尿嘧啶联合超分割胸部放射治疗局部晚期非小细胞肺癌的 II 期研究”，《英国癌症杂志》82・1。 -111 (2000)

Junko Mimoto,Katsuyuki Kiura,Mine Harada, et al.: "(-)-Epigallocatechin Gallate (EGCG) Can Prevent Cisplatin-Induced Lung Tumorigenesis in A/J Mice."Carcinogenesis. 21・5. 915-919 (2000)

Junko Mimoto、Katsuyuki Kiura、Mine Harada 等人：“(-)-表没食子儿茶素没食子酸酯 (EGCG) 可以预防 A/J 小鼠中顺铂诱导的肺肿瘤发生”。致癌作用 21・5。

Mimoto J., Kiura K, Matsuo K, et al.: "(-)-Epigallocatechin Gallate (EGCG) Can Prevent Cisplatin-Induced Lung Tumorigenesis in A/J Mice"Carcinogenesis. 81・4. 104-111 (2000)

Mimoto J.、Kiura K、Matsuo K 等：“(-)-表没食子儿茶素没食子酸酯 (EGCG) 可以预防 A/J 小鼠中顺铂诱导的肺肿瘤发生”81・4 (2000)。

Kawai H, Kiura K, Tabata M., et al.: "Characterization of Non-Small-Cell Lung Cancer Cell Lines Established before an after Chemotherapy."Lung Cancer. 35・3. 305-314 (2002)

Kawai H、Kiura K、Tabata M. 等人：“化疗前后建立的非小细胞肺癌细胞系的特征”35・3 (2002)。